In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
Gerotziafas
G T
GT
Elalamy
I
I
Depasse
F
F
Perzborn
E
E
Samama
M M
MM
D000284:Administration, Oral; D000990:Antithrombin III / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects; D065427:Factor Xa Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D020128:Inhibitory Concentration 50; D007700:Kinetics; D009025:Morpholines / Q000494:pharmacology*; D011516:Prothrombin / Q000378:metabolism; D000069552:Rivaroxaban; D013876:Thiophenes / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013918:Thrombin Time; D013925:Thromboplastin / Q000378:metabolism*; D013997:Time Factors
D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000990:Antithrombin III; D011516:Prothrombin; D013925:Thromboplastin; D000069552:Rivaroxaban; D013917:Thrombin